The first patient has been dosed in a phase 2 clinical trial investigating MCO-010 ambient light activatable optogenetic monotherapy for Stargardt disease, according to a press release from Nanoscope Therapeutics.
The STARLIGHT open-label trial will include approximately six patients set to receive 1.2E11 gc/eye of MCO-010, the same dose that was used in a phase 2b retinitis pigmentosa study. Safety and efficacy data for the first 6 months of the trial are expected in the first quarter of 2023.
“Existing experimental treatments for Stargardt primarily aim to slow progression of vision loss,”